Alexion Pharmaceuticals EVP Unloads $4,160,500 in Stock (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) EVP Martin Mackay sold 25,000 shares of Alexion Pharmaceuticals stock on the open market in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $166.42, for a total transaction of $4,160,500.00. Following the transaction, the executive vice president now directly owns 24,426 shares of the company’s stock, valued at approximately $4,064,975. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.35% on Friday, hitting $163.73. The stock had a trading volume of 1,032,123 shares. Alexion Pharmaceuticals has a 52-week low of $87.01 and a 52-week high of $185.43. The stock’s 50-day moving average is $161.0 and its 200-day moving average is $152.3. The company has a market cap of $32.385 billion and a price-to-earnings ratio of 100.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.53 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.26 by $0.27. The company had revenue of $566.60 million for the quarter, compared to the consensus estimate of $560.22 million. During the same quarter in the prior year, the company posted $0.65 earnings per share. The company’s quarterly revenue was up 67.2% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $4.87 EPS for the current fiscal year.
A number of research firms have recently commented on ALXN. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, May 9th. They now have a $210.00 price target on the stock, up previously from $200.00. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Alexion Pharmaceuticals in a research note on Friday, April 25th. They now have a $187.00 price target on the stock. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, April 25th. They now have a $220.00 price target on the stock, up previously from $219.00. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $182.31.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.